Monkeypox Testing Market

Monkeypox Testing Market Analysis and Forecast by Fact.MR

• The sustained global transmission of monkeypox virus and the growing demand for rapid molecular diagnostics in outbreak response and endemic surveillance settings

Summary of Monkeypox Testing Market

• Market Snapshot
  • In 2025, the global Monkeypox Testing Market was valued at approximately USD 2.2 billion.
  • The market is estimated to reach USD 2.3 billion in 2026 and is projected to attain USD 3.53 billion by 2036.
  • The monkeypox testing market is likely to expand at a CAGR of 4.4% during the forecast period.
  • The market is anticipated to create an absolute dollar opportunity of USD 1.23 billion between 2026 and 2036.
  • PCR Testing Kits accounts for 49.1% of product share in 2026.
  • India (5.9%) and USA (5.6%) are the key growth markets during the forecast period.
• Demand and Growth Drivers
  • Sustained global monkeypox transmission across endemic and newly affected regions is maintaining diagnostic testing demand.
  • Government investment in diagnostic preparedness and stockpiling programs is creating institutional procurement demand for testing kits.
  • Growing adoption of molecular diagnostics over clinical diagnosis alone is increasing test utilization rates.
  • Expansion of point-of-care testing capability in primary care and sexual health clinics is improving testing access.
  • Development of multiplex panels differentiating monkeypox from clinically similar infections is increasing per-test value.
• Product and Segment View
  • PCR Testing Kits accounts for 49.1% of the product segment in 2026, supported by broad applicability across primary end-use categories.
  • Hospitals and Clinics represents 37% of the end user segment in 2026, reflecting sustained institutional demand.
  • Key segmentation includes: Product: PCR, Lateral Flow Assay, Others. Technology: Hospitals and Clinics, Diagnostic Laboratories, Others. End User: Clinical Diagnostics, Public Health Screening, Research Applications. Application: Centralized Testing, Decentralized Testing, Home Testing.
• Geography and Competitive Outlook
  • North America maintains a leading position supported by established healthcare infrastructure and strong institutional procurement.
  • Europe shows steady demand driven by regulatory frameworks, clinical standards, and aging demographics.
  • Asia Pacific is the fastest-growing region, led by India (5.9%) and USA (5.6%).
  • Key players include Labcorp, Quest Diagnostics, Sonic Healthcare, QIAGEN, Aegis Sciences, Mayo Clinic Laboratories.
• Analyst Opinion
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, says 'The monkeypox testing market has moved beyond emergency response into endemic surveillance. Public health laboratories are building standing diagnostic capacity rather than relying on outbreak-triggered procurement. The commercial opportunity is in multiplex panels that detect monkeypox alongside other vesicular rash pathogens, creating higher per-test value and year-round utility beyond outbreak peaks.'

Key Growth Drivers, Constraints, and Opportunities

Key Factors Driving Growth

• Rising disease prevalence and aging populations are expanding the addressable patient population requiring specialized products.
• Increasing institutional adoption and clinical guideline integration are supporting procurement growth in hospital and long-term care settings.
• Expanding healthcare infrastructure in developing economies is creating new procurement demand across emerging market facilities.

Key Market Constraints

• Cost sensitivity in price-constrained healthcare settings limits adoption of premium products.
• Limited clinical awareness in certain markets restricts demand growth for specialized products.
• Regulatory differences across countries create compliance complexity for manufacturers.

Key Opportunity Areas

• Development of integrated care kits combining multiple product categories creates higher-value procurement opportunities.
• Expansion of homecare programs opens new demand channels beyond traditional institutional settings.
• Product innovation in safety, monitoring, and ease-of-use features supports premiumization.

Segment-wise Analysis of the Monkeypox Testing Market

• PCR Testing Kits holds 49.1% of the product segment in 2026.
• Hospitals and Clinics represents 37% of the end user segment in 2026.

The monkeypox testing market is segmented by product, technology, end user, application, and region.

Which Product Segment Dominates the Monkeypox Testing Market?

PCR Testing Kits is expected to account for approximately 49.1% of the product segment in 2026. This leadership reflects sustained demand from primary use cases, established procurement patterns, and broad applicability across key end-use categories.

Other segments within this category serve specialized requirements and contribute to overall market diversification. Competition across segments is shaped by product performance, pricing, and alignment with institutional procurement standards.

Which End User Segment Dominates the Monkeypox Testing Market?

Hospitals and Clinics is expected to account for approximately 37% of the end user segment in 2026. Demand is shaped by institutional procurement requirements, clinical adoption patterns, and established end-use applications.

Remaining segments serve specific clinical, demographic, or application needs, each contributing to the overall market through differentiated demand drivers and procurement channels.

Which Product Trend is Shaping the Next Phase of Growth in the Monkeypox Testing Market?

Multiplex PCR panels that simultaneously detect monkeypox, varicella, and herpes simplex viruses are emerging as the fastest-growing product category. Their adoption is projected to rise as diagnostic laboratories shift from single-pathogen assays toward syndromic panels that provide differential diagnosis for vesicular rash presentations in a single test run. This is particularly relevant in emergency and outbreak settings where rapid differentiation between clinically similar conditions shapes treatment and containment decisions.

The shift toward multiplex testing reflects a broader change in infectious disease diagnostics. Laboratories are moving from sequential testing algorithms toward panel-based workflows that reduce time-to-diagnosis and eliminate the need for multiple sample collections. As a result, multiplex PCR platforms designed for poxvirus detection alongside other rash-causing pathogens are gaining procurement preference, especially in public health laboratories preparing for sustained endemic transmission.

Regional Outlook Across Key Markets

• India leads growth at 5.9%, supported by expanding healthcare infrastructure and rising demand for specialized products.
• USA follows at 5.6%, driven by government healthcare programs and increasing clinical adoption.
• Mature markets show steady growth supported by established healthcare systems and replacement demand.

CAGR Table

Source: Fact MR (FMR) analysis, based on proprietary forecasting model and primary research.

Market Outlook for Monkeypox Testing in India

The India monkeypox testing market is projected to grow at a CAGR of 5.9% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Demand Trends in Monkeypox Testing in USA

The USA monkeypox testing market is projected to grow at a CAGR of 5.6% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Growth Assessment for Monkeypox Testing in Brazil

The Brazil monkeypox testing market is projected to grow at a CAGR of 5.2% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Market Analysis of Monkeypox Testing in Germany

The Germany monkeypox testing market is projected to grow at a CAGR of 4.9% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Opportunity Outlook for Monkeypox Testing in UK

The UK monkeypox testing market is projected to grow at a CAGR of 4.7% through 2036. Demand is supported by expanding healthcare infrastructure and rising institutional investment.

• Healthcare infrastructure expansion supports procurement growth.
• Clinical adoption rates continue to improve across key facilities.
• Government programs and regulatory frameworks support market development.

Competitive Benchmarking and Company Positioning

Monkeypox Testing Market Analysis By Company

• Labcorp, Quest Diagnostics, Sonic Healthcare hold strong positions through broad portfolios and established distribution networks.
• QIAGEN, Aegis Sciences, Mayo Clinic Laboratories compete across specific segments, price tiers, and regional markets.
• Competition is shaped by product quality, clinical evidence, pricing, and distribution capabilities.

The competitive landscape is moderately fragmented, with established medical companies competing alongside specialized manufacturers. Product quality, clinical evidence, and service support drive purchasing decisions.

Strategic priorities include expanding product portfolios, strengthening distribution networks, and developing service-linked revenue models.

Key Companies in the Monkeypox Testing Market

Labcorp, Quest Diagnostics, Sonic Healthcare, QIAGEN are among the leading players. Aegis Sciences, Mayo Clinic Laboratories, Chembio Diagnostics, Sonora Quest Laboratories hold established positions. Thermo Fisher Scientific, BD (Becton, Dickinson and Company) compete through focused product offerings.

Recent Industry Developments

• Labcorp - Product Portfolio Expansion (January 2026)
  • Labcorp expanded its product portfolio targeting growing demand segments.
• Quest Diagnostics - Market Expansion (2025)
  • Quest Diagnostics broadened geographic presence through distribution partnerships.
• Sonic Healthcare - Technology Enhancement (2025)
  • Sonic Healthcare introduced technology improvements targeting performance and compliance.

Leading Companies Shaping the Monkeypox Testing Market

• Labcorp
• Quest Diagnostics
• Sonic Healthcare
• QIAGEN
• Aegis Sciences
• Mayo Clinic Laboratories
• Chembio Diagnostics
• Sonora Quest Laboratories
• Thermo Fisher Scientific
• BD (Becton, Dickinson and Company)

Sources and Research References

• Labcorp. Product portfolio and corporate updates.
• Quest Diagnostics. Product launches and market announcements.
• World Health Organization. Disease prevalence and healthcare infrastructure data.
• Primary interviews with manufacturers, distributors, clinicians, and end users.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

Key Questions This Report Addresses

• What is the current and future size of the Monkeypox Testing Market?
• How fast is the market expected to grow between 2026 and 2036?
• Which product is likely to lead the market by 2026?
• Which end user segment accounts for the highest demand?
• What factors are driving demand globally?
• Which countries show the fastest growth through 2036?
• Who are the key companies in the Monkeypox Testing Market?
• How does Fact.MR estimate and validate the forecast?
• What are the key constraints and opportunities?
• How is product innovation influencing growth?

Monkeypox Testing Market Definition

the sustained global transmission of monkeypox virus and the growing demand for rapid molecular diagnostics in outbreak response and endemic surveillance settings

Monkeypox Testing Market Inclusions

• The scope covers global and regional market size and forecasts for 2026 to 2036 across key segmentation categories and regions.
• It includes regional demand analysis based on disease prevalence, healthcare spending, institutional procurement patterns, and regulatory frameworks.
• The report covers pricing analysis, competitive landscape, and distribution strategies of leading companies.
• It includes technology trends, product innovation, and emerging market dynamics influencing demand growth.

Monkeypox Testing Market Exclusions

• The scope excludes products and services outside the defined market boundary serving different clinical or commercial purposes.
• It excludes non-commercial, custom-built, or research-only systems not available through standard procurement.
• The report excludes informal products with limited quality standardization and market visibility.
• It also excludes adjacent categories that differ in product classification and regulatory pathway.

Monkeypox Testing Market Research Methodology

• The methodology combines secondary research, primary interviews, and forecast modelling.
• It draws on 120+ secondary sources and benchmarks 65+ company product portfolios.
• Market sizing covers 30+ countries through a demand-side model, supported by top-down validation.
• The model cross-checks demand with shipments, pricing trends, channel mix, and product launches.
• Primary validation includes 25+ interviews across manufacturers, distributors, and end users.
• Final estimates go through trade-flow checks, sales-pattern review, and sensitivity testing.